DNA vaccines for prostate cancer

Pharmacology and Therapeutics

Volumn 174, Issue , 2017, Pages 27-42

  Zahm, Christopher D ^a   Colluru, Viswa Teja ^a   McNeel, Douglas G ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

DNA vaccines; Immunotherapy; Mechanism of action; Prostate cancer

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL DNA; CHEMOATTRACTANT; DABRAFENIB; DNA VACCINE; IPILIMUMAB; MARAVIROC; NIVOLUMAB; PEMBROLIZUMAB; PLASMID DNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SUNITINIB; TASQUINIMOD; TOLL LIKE RECEPTOR AGONIST; TRAMETINIB; TUMOR VACCINE; VEMURAFENIB; CANCER VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; DNA TRANSFECTION; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TRANSGENICS; TUMOR MICROENVIRONMENT; VACCINE IMMUNOGENICITY; ANIMAL; IMMUNOLOGY; MALE; PROSTATE TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; HUMANS; IMMUNITY, INNATE; MALE; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINES, DNA;

EID: 85013076666     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.016     Document Type: Review

References (223)

1. Adeegbe, D.O., Nishikawa, H., Natural and induced T regulatory cells in cancer. Frontiers in Immunology, 4, 2013, 190.
2. Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., Stockinger, B., DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. The Journal of Experimental Medicine 189 (1999), 169–178.
3. Akins, E.J., Moore, M.L., Tang, S., Willingham, M.C., Tooze, J.A., Dubey, P., In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Research 70 (2010), 3473–3482.
4. Allan, S., Antigen presentation: Prime time: Insights into cross-presentation. Nature Reviews. Immunology 8 (2008), 322–323.
5. Babiuk, S., Mookherjee, N., Pontarollo, R., Griebel, P., Van Drunen Littel-Van Den Hurk, S., Hecker, R., Babiuk, L., TLR9 −/− and TLR9 +/+ mice display similar immune responses to a DNA vaccine. Immunology 113 (2004), 114–120.
6. Baniyash, M., Myeloid-derived suppressor cells as intruders and targets: Clinical implications in cancer therapy. Cancer Immunology, Immunotherapy 65 (2016), 857–867.
7. Barber, G.N., Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Current Opinion in Immunology 23 (2011), 10–20.
8. Becker, J.T., Olson, B.M., Johnson, L.E., Davies, J.G., Dunphy, E.J., McNeel, D.G., DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. Journal of Immunotherapy 33 (2010), 639–647.
9. Blum, J.S., Wearsch, P.A., Cresswell, P., Pathways of antigen processing. Annual Review of Immunology 31 (2013), 443–473.
10. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine 373 (2015), 1627–1639.
11. Bot, A., Stan, A.C., Inaba, K., Steinman, R., Bona, C., Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer. International Immunology 12 (2000), 825–832.
12. Bouloc, A., Walker, P., Grivel, J.-C., Vogel, J.C., Katz, S.I., Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells. European Journal of Immunology 29 (1999), 446–454.
13. Bowne, W.B., Srinivasan, R., Wolchok, J.D., Hawkins, W.G., Blachere, N.E., Dyall, R.,.. Houghton, A.N., Coupling and uncoupling of tumor immunity and autoimmunity. The Journal of Experimental Medicine 190 (1999), 1717–1722.
14. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 28 (2010), 3167–3175.
15. Bramson, J.L., Dayball, K., Hall, J.R., Millar, J.B., Miller, M., Wan, Y.H.,.. Hiscott, J., Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine 21 (2003), 1363–1370.
16. Cao, M., Xu, Y., Youn, J., Cabrera, R., Zhang, X., Gabrilovich, D.,.. Liu, C., Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Laboratory Investigation 91 (2011), 598–608.
17. Casares, S., Inaba, K., Brumeanu, T.-D., Steinman, R.M., Bona, C.A., Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II–restricted viral epitope. The Journal of Experimental Medicine 186 (1997), 1481–1486.
18. Chen, Z.-Y., He, C.-Y., Ehrhardt, A., Kay, M.A., Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy: The Journal of the American Society of Gene Therapy 8 (2003), 495–500.
19. Chen, S.-P., Peng, R.-H., Chiou, P.P., Modulatory effect of CpG oligodeoxynucleotide on a DNA vaccine against nervous necrosis virus in orange-spotted grouper (Epinephelus coioides). Fish & Shellfish Immunology 45 (2015), 919–926.
20. Cho, J.H., Youn, J.W., Sung, Y.C., Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. Journal of Immunology 167 (2001), 5549–5557.
21. Choi, T., Huang, M., Gorman, C., Jaenisch, R., A generic intron increases gene expression in transgenic mice. Molecular and Cellular Biology 11 (1991), 3070–3074.
22. Chuang, I., Sedegah, M., Cicatelli, S., Spring, M., Polhemus, M., Tamminga, C., Patterson, N., Guerrero, M., Bennett, J.W., McGrath, S., et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PloS One, 8, 2013, e55571.
23. Chudley, L., McCann, K., Mander, A., Tjelle, T., Campos-Perez, J., Godeseth, R., Creak, A., Dobbyn, J., Johnson, B., Bass, P., et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunology, Immunotherapy 61 (2012), 2161–2170.
24. Churchyard, G.J., Morgan, C., Adams, E., Hural, J., Graham, B.S., Moodie, Z., Grove, D., Gray, G., Bekker, L.-G., McElrath, M.J., et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PloS One, 6, 2011, e21225.
25. Coban, C., Kobiyama, K., Aoshi, T., Takeshita, F., Horii, T., Akira, S., Ishii, K.J., Novel strategies to improve DNA vaccine immunogenicity. Current Gene Therapy 11 (2011), 479–484.
26. Coelho-Castelo, A.A.M., Santos, R.R., Bonato, V.L.D., Jamur, M.C., Oliver, C., Silva, C.L., B-lymphocytes in bone marrow or lymph nodes can take up plasmid DNA after intramuscular delivery. Human Gene Therapy 14 (2003), 1279–1285.
27. Colluru, V.T., Johnson, L.E., Olson, B.M., McNeel, D.G., Preclinical and clinical development of DNA vaccines for prostate cancer. Urologic Oncology 34 (2013), 193–204.
28. Colluru, V.T., McNeel, D.G., B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget, 5, 2016.
29. Colluru, V.T., Zahm, C.D., McNeel, D.G., Mini-intronic plasmid vaccination elicits tolerant LAG3 + CD8 T cells and inferior anti-tumor responses. Oncoimmunology, 5(10), 2016, e1223002.
30. Corr, M., von Damm, A., Lee, D.J., Tighe, H., In vivo priming by DNA injection occurs predominantly by antigen transfer. Journal of Immunology 163 (1999), 4721–4727.
31. Corse, E., Gottschalk, R.A., Krogsgaard, M., Allison, J.P., Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biology, 8, 2010, e1000481.
32. Curran, M.A., Allison, J.P., Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Research 69 (2009), 7747–7755.
33. Dalrymple, S.L., Becker, R.E., Isaacs, J.T., The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 67 (2007), 790–797.
34. de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M.J., Shen, L., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376 (2010), 1147–1154.
35. de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman, O.B., Saad, F., et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine 364 (2011), 1995–2005.
36. Debnath, B., Xu, S., Grande, F., Garofalo, A., Neamati, N., Small molecule inhibitors of CXCR4. Theranostics 3 (2013), 47–75.
37. Desmet, C.J., Ishii, K.J., Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nature Reviews. Immunology 12 (2012), 479–491.
38. Diaz, C.M., Chiappori, A., Aurisicchio, L., Bagchi, A., Clark, J., Dubey, S., Fridman, A., Fabregas, J.C., Marshall, J., Scarselli, E., et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Journal of Translational Medicine, 11, 2013, 62.
39. Dietz, W.M., Skinner, N.E.B., Hamilton, S.E., Jund, M.D., Heitfeld, S.M., Litterman, A.J., Hwu, P., Chen, Z.-Y., Salazar, A.M., Ohlfest, J.R., et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8 + T-cell responses. Molecular Therapy 21 (2013), 1526–1535.
40. Diniz, M.O., Sales, N.S., Silva, J.R., Ferreira, L.C.S., Protection against HPV-16-associated tumors requires the activation of CD8 + effector memory T cells and the control of myeloid-derived suppressor cells. Molecular Cancer Therapeutics 15 (2016), 1920–1930.
41. Disis, M.L., Shiota, F.M., McNeel, D.G., Knutson, K.L., Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology 207 (2003), 179–186.
42. Dong, Y., Yang, J., Zhang, J., Zhang, X., Nano-delivery vehicles/adjuvants for DNA vaccination against HIV. Journal of Nanoscience and Nanotechnology 16 (2016), 2126–2133.
43. Donnelly, J.J., Friedman, A., Martinez, D., Montgomery, D.L., Shiver, J.W., Motzel, S.L.,.. Liu, M.A., Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nature Medicine 1 (1995), 583–587.
44. Dowling, J.K., Mansell, A., Toll-like receptors: The swiss army knife of immunity and vaccine development. Clinical and Translational Immunology, 5, 2016, e85.
45. Dürrbach, A., Angevin, E., Poncet, P., Rouleau, M., Chavanel, G., Chapel, A., Thierry, D., Gorter, A., Hirsch, R., Charpentier, B., et al. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Therapy 6 (1999), 564–571.
46. Eriksson, F., Tötterman, T., Maltais, A.-K., Pisa, P., Yachnin, J., DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine 31 (2013), 3843–3848.
47. Fan, Z., Kumon, R.E., Deng, C.X., Mechanisms of microbubble-facilitated sonoporation for drug and gene delivery. Therapeutic Delivery 5 (2014), 467–486.
48. Farris, E., Brown, D.M., Ramer-Tait, A.E., Pannier, A.K., Micro- and nanoparticulates for DNA vaccine delivery. Experimental Biology and Medicine 241 (2016), 919–929.
49. Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., Alnemri, E.S., AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458 (2009), 509–513.
50. Filaci, G., Gerloni, M., Rizzi, M., Castiglioni, P., Chang, H.-D., Wheeler, M.C.,.. Zanetti, M., Spontaneous transgenesis of human B lymphocytes. Gene Therapy 11 (2004), 42–51.
51. Flingai, S., Czerwonko, M., Goodman, J., Kudchodkar, S.B., Muthumani, K., Weiner, D.B., Synthetic DNA vaccines: Improved vaccine potency by electroporation and co-delivered genetic adjuvants. Immunotherapy and Vaccines, 4, 2013, 354.
52. Frederick, D.T., Piris, A., Cogdill, A.P., Cooper, Z.A., Lezcano, C., Ferrone, C.R., Mitra, D., Boni, A., Newton, L.P., Liu, C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research 19 (2013), 1225–1231.
53. Frelin, L., Ahlén, G., Alheim, M., Weiland, O., Barnfield, C., Liljeström, P., Sällberg, M., Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Therapy 11 (2004), 522–533.
54. Fu, T.M., Friedman, A., Ulmer, J.B., Liu, M.A., Donnelly, J.J., Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. Journal of Virology 71 (1997), 2715–2721.
55. Fu, T.M., Ulmer, J.B., Caulfield, M.J., Deck, R.R., Friedman, A., Wang, S.,.. Liu, M.A., Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Molecular Medicine 3 (1997), 362–371.
56. Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., Mechette, K., Leong, J.J., Lauer, P., Liu, W., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Science Translational Medicine, 7, 2015, 283ra52.
57. Gableh, F., Saeidi, M., Hemati, S., Hamdi, K., Soleimanjahi, H., Gorji, A., Ghaemi, A., Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. Journal of Biomedical Science, 23, 2016, 16.
58. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology 12 (2012), 253–268.
59. Garcia-Hernandez, M.d.l.L., Gray, A., Hubby, B., Klinger, O.J., Kast, W.M., Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Research 68 (2008), 861–869.
60. Garmory, H.S., Brown, K.A., Titball, R.W., DNA vaccines: Improving expression of antigens. Genetic Vaccines and Therapy, 1, 2003, 2.
61. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine 372 (2015), 2018–2028.
62. Garu, A., Moku, G., Gulla, S.K., Chaudhuri, A., Genetic immunization with in vivo dendritic cell targeting liposomal DNA vaccine carrier induces long-lasting anti-tumor immune response. Molecular Therapy 24 (2016), 385–397.
63. Gerloni, M., Rizzi, M., Castiglioni, P., Zanetti, M., T cell immunity using transgenic B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 101 (2004), 3892–3897.
64. Gnjatic, S., Altorki, N.K., Tang, D.N., Tu, S.-M., Kundra, V., Ritter, G.,.. Sharma, P., NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clinical Cancer Research 15 (2009), 2130–2139.
65. Gregor, P.D., Wolchok, J.D., Ferrone, C.R., Buchinshky, H., Guevara-Patiño, J.A., Perales, M.-A., Mortazavi, F., Bacich, D., Heston, W., Latouche, J.-B., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22 (2004), 1700–1708.
66. Grosenbaugh, D.A., Leard, A.T., Bergman, P.J., Klein, M.K., Meleo, K., Susaneck, S., Hess, P.R., Jankowski, M.K., Jones, P.D., Leibman, N.F., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 72 (2011), 1631–1638.
67. Hawkins, W.G., Gold, J.S., Dyall, R., Wolchok, J.D., Hoos, A., Bowne, W.B.,.. Lewis, J.J., Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128 (2000), 273–280.
68. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000), 740–745.
69. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E.,.. Mackall, C.L., Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Science Translational Medicine, 6, 2014, 237ra67.
70. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 363 (2010), 711–723.
71. Hon, H., Oran, A., Brocker, T., Jacob, J., B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. Journal of Immunology 174 (2005), 5233–5242.
72. Hoppes, R., Oostvogels, R., Luimstra, J.J., Wals, K., Toebes, M., Bies, L., Ekkebus, R., Rijal, P., Celie, P.H.N., Huang, J.H., et al. Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes. Journal of Immunology 193 (2014), 4803–4813.
73. Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R.,.. Fitzgerald, K.A., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458 (2009), 514–518.
74. Hurwitz, A.A., Foster, B.A., Kwon, E.D., Truong, T., Choi, E.M., Greenberg, N.M.,.. Allison, J.P., Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Research 60 (2000), 2444–2448.
75. Igoucheva, O., Grazzini, M., Pidich, A., Kemp, D.M., Larijani, M., Farber, M.,.. Alexeev, V., Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine. Gene Therapy 20 (2013), 939–948.
76. Isaacs, J.T., Antony, L., Dalrymple, S.L., Brennen, W.N., Gerber, S., Hammers, H., Wissing, M., Kachhap, S., Luo, J., Xing, L., et al. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research 73 (2013), 1386–1399.
77. Ishikawa, H., Ma, Z., Barber, G.N., STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461 (2009), 788–792.
78. Iwasaki, A., Medzhitov, R., Regulation of adaptive immunity by the innate immune system. Science 327 (2010), 291–295 (80-.).
79. Jacob, J.B., Kong, Y.M., Nalbantoglu, I., Snower, D.P., Wei, W.-Z., Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. Journal of Immunology 182 (2009), 5873–5881.
80. Joffre, O.P., Segura, E., Savina, A., Amigorena, S., Cross-presentation by dendritic cells. Nature Reviews. Immunology 12 (2012), 557–569.
81. Johnson, L.E., Frye, T.P., McNeel, D.G., Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. OncoImmunology 1 (2012), 1546–1556.
82. Kaczanowska, S., Joseph, A.M., Davila, E., TLR agonists: Our best frenemy in cancer immunotherapy. Journal of Leukocyte Biology 93 (2013), 847–863.
83. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 363 (2010), 411–422.
84. Kapadia, D., Sadikovic, A., Vanloubbeeck, Y., Brockstedt, D., Fong, L., Interplay between CD8α + dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses. PloS One, 6, 2011, e19376.
85. Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S.K., Dubois, R.N., CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24 (2013), 631–644.
86. Kay, M.A., He, C.-Y., Chen, Z.-Y., A robust system for production of minicircle DNA vectors. Nature Biotechnology 28 (2010), 1287–1289.
87. Khalili, J.S., Liu, S., Rodríguez-Cruz, T.G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z.A., Frederick, D.T., Li, Y., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clinical Cancer Research 18 (2012), 5329–5340.
88. Kiniwa, Y., Miyahara, Y., Wang, H.Y., Peng, W., Peng, G., Wheeler, T.M.,.. Wang, R.-F., CD8 + Foxp3 + regulatory T cells mediate immunosuppression in prostate cancer. Clinical Cancer Research 13 (2007), 6947–6958.
89. Kirkwood, J.M., Butterfield, L.H., Tarhini, A.A., Zarour, H., Kalinski, P., Ferrone, S., Immunotherapy of cancer in 2012. CA: a Cancer Journal for Clinicians 62 (2012), 309–335.
90. Klyushnenkova, E.N., Riabov, V.B., Kouiavskaia, D.V., Wietsma, A., Zhan, M., Alexander, R.B., Breaking immune tolerance by targeting CD25 + regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate 74 (2014), 1423–1432.
91. Ko, J.S., Zea, A.H., Rini, B.I., Ireland, J.L., Elson, P., Cohen, P., Golshayan, A., Rayman, P.A., Wood, L., Garcia, J., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research 15 (2009), 2148–2157.
92. Kobiyama, K., Jounai, N., Aoshi, T., Tozuka, M., Takeshita, F., Coban, C., Ishii, K.J., Innate immune signaling by, and genetic adjuvants for DNA vaccination. Vaccine 1 (2013), 278–292.
93. Krupa, M., Canamero, M., Gomez, C.E., Najera, J.L., Gil, J., Esteban, M., Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29 (2011), 1504–1513.
94. Kursar, M., Bonhagen, K., Fensterle, J., Köhler, A., Hurwitz, R., Kamradt, T.,.. Mittrücker, H.-W., Regulatory CD4 + CD25 + T cells restrict memory CD8 + T cell responses. The Journal of Experimental Medicine 196 (2002), 1585–1592.
95. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J.M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology 15 (2014), 700–712.
96. Lambracht-Washington, D., Qu, B., Fu, M., Anderson, L.D., Eagar, T.N., Stüve, O., Rosenberg, R.N., A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. Journal of Neuroimmunology 254 (2013), 63–68.
97. Layek, B., Lipp, L., Singh, J., APC targeted micelle for enhanced intradermal delivery of hepatitis B DNA vaccine. Journal of Controlled Release 207 (2015), 143–153.
98. Lazoura, E., Lodding, J., Farrugia, W., Ramsland, P.a., Stevens, J., Wilson, I.a.,.. Apostolopoulos, V., Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology 119 (2006), 306–316.
99. Ledgerwood, J.E., Wei, C.-J., Hu, Z., Gordon, I.J., Enama, M.E., Hendel, C.S., McTamney, P.M., Pearce, M.B., Yassine, H.M., Boyington, J.C., et al. DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. The Lancet Infectious Diseases 11 (2011), 916–924.
100. Lee, I.H., Park, J.-B., Cheong, M., Choi, Y.S., Park, D., Sin, J.-I., Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: A possible mechanism for enhanced tumor control. DNA and Cell Biology 30 (2011), 975–985.
101. Lee, J., Li, L., Gretz, N., Gebert, J., Dihlmann, S., Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene 31 (2012), 1242–1253.
102. Li, J., Shi, J.-L., Wu, X.-Y., Fu, F., Yu, J., Yuan, X.-Y., Peng, Z., Cong, X.-Y., Xu, S.-J., Sun, W.-B., et al. Improvement of the immunogenicity of porcine circovirus type 2 DNA vaccine by recombinant ORF2 gene and CpG motifs. Viral Immunology 28 (2015), 290–296.
103. Lin, C.-T., Tsai, Y.-C., He, L., Calizo, R., Chou, H.-H., Chang, T.-C.,.. Lai, C.-H., A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Journal of Biomedical Science 13 (2006), 481–488.
104. Ling Yong, C.L., Siak-Wei Ow, D., Tandiono, T., Mei Heng, L.L., Kwok-Keung Chan, K., Ohl, C.-D.,.. Boon-Hwa Choo, A., Microbubble-mediated sonoporation for highly efficient transfection of recalcitrant human B- cell lines. Biotechnology Journal 9 (2014), 1081–1087.
105. Liu, M.A., DNA vaccines: An historical perspective and view to the future. Immunological Reviews 239 (2011), 62–84.
106. Liu, C., Yue, R., Yang, Y., Cui, Y., Yang, L., Zhao, D., Zhou, X., AIM2 inhibits autophagy and IFN-β production during M. bovis infection. Oncotarget 7 (2016), 46972–46987.
107. Lorenz, F.K.M., Wilde, S., Voigt, K., Kieback, E., Mosetter, B., Schendel, D.J., Uckert, W., Codon optimization of the human papillomavirus E7 oncogene induces a CD8 + T cell response to a cryptic epitope not harbored by wild-type E7. PloS One, 10, 2015, e0121633.
108. Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I.,.. Ottensmeier, C.H., DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Human Gene Therapy 20 (2009), 1269–1278.
109. Lu, J., Zhang, F., Xu, S., Fire, A.Z., Kay, M.A., The extragenic spacer length between the 5′ and 3′ ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Molecular Therapy 20 (2012), 2111–2119.
110. Lu, J., Zhang, F., Kay, M.A., A mini-intronic plasmid (MIP): A novel robust transgene expression vector in vivo and in vitro. Molecular Therapy 21 (2013), 954–963.
111. Ma, H., Kapp, J.a., Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo. Cellular Immunology 214 (2001), 89–96.
112. MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy, K.E., Gluckman, S.J., Bagarazzi, M.L., Chattergoon, M.A., Baine, Y., Higgins, T.J., Ciccarelli, R.B., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. The Journal of Infectious Diseases 178 (1998), 92–100.
113. Madan, R.A., Arlen, P.M., Mohebtash, M., Hodge, J.W., Gulley, J.L., Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer. Expert Opinion on Investigational Drugs 18 (2009), 1001–1011.
114. Madan, R.A., Gulley, J.L., Fojo, T., Dahut, W.L., Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. The Oncologist 15 (2010), 969–975.
115. Maniar, L.E.G., Maniar, J.M., Chen, Z.-Y., Lu, J., Fire, A.Z., Kay, M.A., Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Molecular Therapy 21 (2012), 131–138.
116. McMahan, R.H., McWilliams, J.A., Jordan, K.R., Dow, S.W., Wilson, D.B., Slansky, J.E., Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. The Journal of Clinical Investigation 116 (2006), 2543–2551.
117. McNeel, D.G., Prostate cancer immunotherapy. Current Opinion in Urology 17 (2007), 175–181.
118. McNeel, D.G., Disis, M.L., Tumor vaccines for the management of prostate cancer. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 48 (2000), 85–93.
119. McNeel, D.G., Malkovsky, M., Immune-based therapies for prostate cancer. Immunology Letters 96 (2005), 3–9.
120. McNeel, D.G., Dunphy, E.J., Davies, J.G., Frye, T.P., Johnson, L.E., Staab, M.J., Horvath, D.L., Straus, J., Alberti, D., Marnocha, R., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of Clinical Oncology 27 (2009), 4047–4054.
121. McNeel, D.G., Becker, J.T., Johnson, L.E., Olson, B.M., DNA vaccines for prostate cancer. Current Cancer Therapy Reviews 8 (2012), 254–263.
122. McNeel, D.G., Becker, J.T., Eickhoff, J.C., Johnson, L.E., Bradley, E., Pohlkamp, I.,.. Olson, B.M., Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clinical Cancer Research 20 (2014), 3692–3704.
123. McNeel, D.G., Eickhoff, J., Jeraj, R., Staab, M.J., Straus, J., Rekoske, B., Liu, G., DNA vaccine with pembrolizumab elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). 2016 national meeting of the Society for Immunotherapy of Cancer, Washington DC, abstract 369, 2016.
124. Mehta, A.R., Armstrong, A.J., Tasquinimod in the treatment of castrate-resistant prostate cancer - Current status and future prospects. Therapeutic Advances in Urology 8 (2016), 9–18.
125. Melcher, R., Grosch, H.-W., Hasilik, A., Plasmid vectors with a 5′-hybrid intron facilitate high-level glycoprotein expression in CHO-cells. Biochimica et Biophysica Acta - Gene Structure and Expression 1575 (2002), 49–53.
126. Mennuni, C., Calvaruso, F., Facciabene, A., Aurisicchio, L., Storto, M., Scarselli, E.,.. La Monica, N., Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. International Journal of Cancer 117 (2005), 444–455.
127. Miller, A.M., Ozenci, V., Kiessling, R., Pisa, P., Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. Journal of Immunotherapy 28 (1997), 389–395.
128. Miller, A.M., Lundberg, K., Ozenci, V., Banham, A.H., Hellstrom, M., Egevad, L., Pisa, P., CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. Journal of Immunology 177 (2006), 7398–7405.
129. Mincheff, M., Tchakarov, S., Zoubak, S., Loukinov, D., Botev, C., Altankova, I.,.. Meryman, H.T., Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. European Urology 38 (2000), 208–217.
130. Mitsui, M., Nishikawa, M., Zang, L., Ando, M., Hattori, K., Takahashi, Y.,.. Takakura, Y., Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. The Journal of Gene Medicine 11 (2009), 435–443.
131. Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. The Journal of Experimental Medicine 208 (2011), 1949–1962.
132. Morrissey, D., A., S., Rajenderan, S., Casey, G., C., G., Tangney, M., Plasmid transgene expression in vivo: Promoter and tissue variables. Gene therapy - Tools and potential applications, 2013, InTech.
133. Mossadegh, N., Gissmann, L., Müller, M., Zentgraf, H., Alonso, A., Tomakidi, P., Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 326 (2004), 57–66.
134. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. The New England Journal of Medicine 373 (2015), 1803–1813.
135. Moulin, V., Morgan, M.E., Eleveld-Trancikova, D., Haanen, J.B.a.G., Wielders, E., Looman, M.W.G.,.. Adema, G.J., Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Therapy 19 (2012), 303–311.
136. Mousavi Niri, N., Memarnejadian, A., Pilehvar-Soltanahmadi, Y., Agha Sadeghi, M., Mahdavi, M., Kheshtchin, N., Arab, S., Namdar, A., Jadidi, F., Zarghami, N., et al. Improved anti-Treg vaccination targeting Foxp3 efficiently decreases regulatory T cells in mice. Journal of Immunotherapy 39 (2016), 269–275.
137. Muthana, M., Scott, S.D., Farrow, N., Morrow, F., Murdoch, C., Grubb, S.,.. Lewis, C.E., A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Therapy 15 (2008), 902–910.
138. Naftzger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradhi, S., Houghton, A.N., Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 93 (1996), 14809–14814.
139. Nguyen-Hoai, T., Baldenhofer, G., Ahmed, M.S., Pham-Duc, M., Gries, M., Lipp, M.,.. Westermann, J., CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model. The Journal of Gene Medicine 14 (2012), 128–137.
140. Nguyen-Hoai, T., Hohn, O., Vu, M.D., Baldenhofer, G., Sayed Ahmed, M.S., Dörken, B.,.. Westermann, J., CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: Improved vaccine efficacy and a role for B cells as APC. Cancer Gene Therapy 19 (2012), 880–887.
141. Ni, J., Nolte, B., Arnold, A., Fournier, P., Schirrmacher, V., Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine 27 (2009), 5480–5487.
142. Nie, Y., Wang, Y.-Y., Innate immune responses to DNA viruses. Protein & Cell 4 (2013), 1–7.
143. Olsson, A., Björk, A., Vallon-Christersson, J., Isaacs, J.T., Leanderson, T., Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer, 9, 2010, 107.
144. Osborn, M.J., McElmurry, R.T., Lees, C.J., DeFeo, A.P., Chen, Z.-Y., Kay, M.A.,.. Blazar, B.R., Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Molecular Therapy 19 (2011), 450–460.
145. Pal, S.K., Kortylewski, M., Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer. OncoImmunology, 5, 2015, e1078060.
146. Papadakis, E., Nicklin, S., Baker, A., White, S., Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy 4 (2004), 89–113.
147. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 12 (2012), 252–264.
148. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fosså, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine 369 (2013), 213–223.
149. Pavlenko, M., Roos, A.-K., Lundqvist, A., Palmborg, A., Miller, A.M., Ozenci, V., Bergman, B., Egevad, L., Hellström, M., Kiessling, R., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. British Journal of Cancer 91 (2004), 688–694.
150. Pavlenko, M., Leder, C., Moreno, S., Levitsky, V., Pisa, P., Priming of CD8 + T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine 25 (2007), 6341–6347.
151. Peled, A., Abraham, M., Avivi, I., Rowe, J.M., Beider, K., Wald, H., Tiomkin, L., Ribakovsky, L., Riback, Y., Ramati, Y., et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34 + cells in patients with multiple myeloma. Clinical Cancer Research 20 (2014), 469–479.
152. Petrylak, D.P., Tangen, C., Hussain, M., Lara, P.N., Jones, J., Talpin, M.E.,.. Crawford, E.D., SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). ASCO meet. Abstr. 22, 2004, 3.
153. Plank, C., Zelphati, O., Mykhaylyk, O., Magnetically enhanced nucleic acid delivery. Ten years of magnetofection—Progress and prospects. Advanced Drug Delivery Reviews 63 (2011), 1300–1331.
154. Porgador, A., Irvine, K.R., Iwasaki, A., Barber, B.H., Restifo, N.P., Germain, R.N., Predominant role for directly transfected dendritic cells in antigen presentation to CD8 + T cells after gene gun immunization. The Journal of Experimental Medicine 188 (1998), 1075–1082.
155. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C., Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999), 1591–1597.
156. Qin, L., Jiang, G., Han, J., Letvin, N.L., Regulatory T cells modulate DNA vaccine immunogenicity at early time via functional CD4(+) T cells and antigen duration. Frontiers in Immunology, 6, 2015, 510.
157. Raposo, G., Nijman, H.W., Stoorvogel, W., Liejendekker, R., Harding, C.V., Melief, C.J., Geuze, H.J., B lymphocytes secrete antigen-presenting vesicles. The Journal of Experimental Medicine 183 (1996), 1161–1172.
158. Ratsimandresy, R.A., Dorfleutner, A., Stehlik, C., An update on PYRIN domain-containing pattern recognition receptors: From immunity to pathology. Molecular Innate Immunity, 4, 2013, 440.
159. Rekoske, B.T., Smith, H.A., Olson, B.M., Maricque, B.B., McNeel, D.G., PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunology Research 3 (2015), 946–955.
160. Rekoske, B.T., Olson, B.M., McNeel, D.G., Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology, 5, 2016, e1165377.
161. Riu, E., Chen, Z.-Y., Xu, H., He, C.-Y., Kay, M.A., Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Molecular Therapy: The Journal of the American Society of Gene Therapy 15 (2007), 1348–1355.
162. Robbins, P.D., Morelli, A.E., Regulation of immune responses by extracellular vesicles. Nature Reviews. Immunology 14 (2014), 195–208.
163. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 364 (2011), 2517–2526.
164. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine 372 (2015), 320–330.
165. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine 372 (2015), 2521–2532.
166. Rolla, S., Ria, F., Occhipinti, S., Di Sante, G., Iezzi, M., Spadaro, M., Nicolo, C., Ambrosino, E., Merighi, I.F., Musiani, P., et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: Potential and limits of its therapeutic efficacy. Journal of Immunology 184 (2010), 6124–6132.
167. Roos, A.-K., Eriksson, F., Timmons, J.A., Gerhardt, J., Nyman, U., Gudmundsdotter, L.,.. Pisa, P., Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PloS One, 4, 2009, e7226.
168. Roth, F., De La Fuente, A.C., Vella, J.L., Zoso, A., Inverardi, L., Serafini, P., Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., et al. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Research 72 (2012), 1373–1383.
169. Saade, F., Petrovsky, N., Technologies for enhanced efficacy of DNA vaccines. Expert Review of Vaccines 11 (2012), 189–209.
170. Sajadian, A., Tabarraei, A., Soleimanjahi, H., Fotouhi, F., Gorji, A., Ghaemi, A., Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Archives of Virology 159 (2014), 1951–1960.
171. Sakamaki, I., Kwak, L.W., Cha, S., Yi, Q., Lerman, B., Chen, J.,.. Qin, H., Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28 (2014), 329–337.
172. Salama, A., Fichou, N., Allard, M., Dubreil, L., De Beaurepaire, L., Viel, A.,.. Bach, J.-M., MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity. PloS One, 9, 2014, e106153.
173. Santegoets, S.J., Stam, A.G., Lougheed, S.M., Gall, H., Jooss, K., Sacks, N., Hege, K., Lowy, I., Scheper, R.J., Gerritsen, W.R., et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. Journal for Immunotherapy of Cancer, 2, 2014, 31.
174. Sasai, M., Linehan, M.M., Iwasaki, A., Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329 (2010), 1530–1534 (80-.).
175. Sasaki, S., Amara, R.R., Yeow, W.-S., Pitha, P.M., Robinson, H.L., Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. Journal of Virology 76 (2002), 6652–6659.
176. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, K.N., Shore, N.D., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine 367 (2012), 1187–1197.
177. Scherer, F., Anton, M., Schillinger, U., Henke, J., Bergemann, C., Krüger, A.,.. Plank, C., Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Therapy 9 (2002), 102–109.
178. Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A.,.. Paschen, A., Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. International Journal of Cancer 133 (2013), 1653–1663.
179. Schneeberger, A., Wagner, C., Zemann, A., Lührs, P., Kutil, R., Goos, M.,.. Wagner, S.N., CpG motifs are efficient adjuvants for DNA cancer vaccines. The Journal of Investigative Dermatology 123 (2004), 371–379.
180. Shah, M.A.A., Ali, Z., Ahmad, R., Qadri, I., Fatima, K., He, N., DNA mediated vaccines delivery through nanoparticles. Journal of Nanoscience and Nanotechnology 15 (2015), 41–53.
181. Sharma, S., Fitzgerald, K.A., Innate immune sensing of DNA. PLoS Pathogens, 7, 2011, e1001310.
182. Shen, L., Sundstedt, A., Ciesielski, M., Miles, K.M., Celander, M., Adelaiye, R., Orillion, A., Ciamporcero, E., Ramakrishnan, S., Ellis, L., et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research 3 (2015), 136–148.
183. Shirota, H., Petrenko, L., Hattori, T., Klinman, D.M., Contribution of IRF-3 mediated IFNbeta production to DNA vaccine dependent cellular immune responses. Vaccine 27 (2009), 2144–2149.
184. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA: a Cancer Journal for Clinicians 66 (2016), 7–30.
185. Simon, S., Vignard, V., Florenceau, L., Dreno, B., Khammari, A., Lang, F., Labarriere, N., PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology, 5, 2015, e1104448.
186. Slovin, S.F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W.G., Fazzari, M., Dantis, L., et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of Sciences of the United States of America 96 (1999), 5710–5715.
187. Slovin, S., Gregor, P., Wolchok, J., Pedraza, A., Orlandi, F., Jefferson, M., Jefferson, M., Fernandez, C., Rudolph, J., Houghton, A., et al. A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle. ASCO meet. Abstr. 25, 2007, 3073.
188. Smith, H.A., McNeel, D.G., Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. Journal of Immunotherapy 34 (2011), 569–580.
189. Smith, H.a., Rekoske, B.T., McNeel, D.G., DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8 + T-cell immune responses. Vaccine 32 (2014), 1707–1715.
190. Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Kar, U., Huang, M., Johnson, M.F., Lee, J.M., Elashoff, D., Strieter, R., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS One, 7, 2012, e40677.
191. Stan, A.C., Casares, S., Brumeanu, T.D., Klinman, D.M., Bona, C.A., CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. European Journal of Immunology 31 (2001), 301–310.
192. Sun, L., Wu, J., Du, F., Chen, X., Chen, Z.J., Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339 (2012), 786–791.
193. Suschak, J.J., Wang, S., Fitzgerald, K.A., Lu, S., Identification of Aim2 as a sensor for DNA vaccines. Journal of Immunology 194 (2014), 630–636.
194. Suschak, J.J., Wang, S., Fitzgerald, K.A., Lu, S., A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines. Journal of Immunology (Baltimore, Md.: 1950) 196 (2016), 310–316.
195. Tang, S., Moore, M.L., Grayson, J.M., Dubey, P., Increased CD8 + T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Research 72 (2012), 1975–1985.
196. Théry, C., Zitvogel, L., Amigorena, S., Exosomes: Composition, biogenesis and function. Nature Reviews. Immunology 2 (2002), 569–579.
197. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366 (2012), 2443–2454.
198. Ulmer, J.B., Otten, G.R., Priming of CTL responses by DNA vaccines: Direct transfection of antigen presenting cells versus cross-priming. Developmental Biology (Basel) 104 (2000), 9–14.
199. Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki, V.J.,.. Friedman, A., Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993), 1745–1749.
200. Un, K., Kawakami, S., Suzuki, R., Maruyama, K., Yamashita, F., Hashida, M., Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier. Molecular Pharmaceutics 8 (2011), 543–554.
201. Unterholzner, L., Keating, S.E., Baran, M., Horan, K.A., Jensen, S.B., Sharma, S., Sirois, C.M., Jin, T., Latz, E., Xiao, T.S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nature Immunology 11 (2010), 997–1004.
202. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 9 (2007), 654–659.
203. van den Eertwegh, A.J.M., Versluis, J., van den Berg, H.P., Santegoets, S.J.A.M., van Moorselaar, R.J.A., van der Sluis, T.M., Gall, H.E., Harding, T.C., Jooss, K., Lowy, I., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. The Lancet Oncology 13 (2012), 509–517.
204. Vandermeulen, G., Richiardi, H., Escriou, V., Ni, J., Fournier, P., Schirrmacher, V.,.. Préat, V., Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine 27 (2009), 4272–4277.
205. Wagner, H., The immunobiology of the TLR9 subfamily. Trends in Immunology 25 (2004), 381–386.
206. Wang, Q., Jiang, W., Chen, Y., Liu, P., Sheng, C., Chen, S.,.. Huang, W., In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. Journal of Virology 88 (2013), 1924–1934.
207. Ward, J.E., McNeel, D.G., GVAX: An allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy 7 (2007), 1893–1902.
208. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Lao, C.D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology 16 (2015), 375–384.
209. Weitzenfeld, P., Ben-Baruch, A., The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Letters 352 (2014), 36–53.
210. Wen, F.T., Thisted, R.A., Rowley, D.A., Schreiber, H., A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. OncoImmunology 1 (2012), 172–178.
211. Williams, J.A., Vector design for improved DNA vaccine efficacy, safety and production. Vaccine 1 (2013), 225–249.
212. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., Direct gene transfer into mouse muscle in vivo. Science 247 (1990), 1465–1468.
213. Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., Chen, Z.J., Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339 (2012), 826–830.
214. Xiang, Z.Q., Spitalnik, S., Tran, M., Wunner, W.H., Cheng, J., Ertl, H.C., Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199 (1994), 132–140.
215. Xiang, L., Bin, W., Huali, J., Wei, J., Jiesheng, T., Feng, G., Ying, L., Bacterial magnetic particles (BMPs)-PEI as a novel and efficient non-viral gene delivery system. The Journal of Gene Medicine 9 (2007), 679–690.
216. Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S.H., Hoon, D.S.B., Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Molecular Therapy: The Journal of the American Society of Gene Therapy 13 (2006), 194–202.
217. Yamano, T., Kaneda, Y., Hiramatsu, S.H., Huang, S., Tran, A.N., Giuliano, A.E., Hoon, D.S.B., Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Therapy 14 (2007), 451–459.
218. Yan, M., Jene, N., Byrne, D., Millar, E.K.A., O'Toole, S.A., McNeil, C.M., Bates, G.J., Harris, A.L., Banham, A.H., Sutherland, R.L., et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research, 13, 2011, R47.
219. Yan, J., Tingey, C., Lyde, R., Gorham, T.C., Choo, D.K., Muthumani, A., Myles, D., Weiner, L.P., Kraynyak, K.A., Reuschel, E.L., et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Therapy 21 (2014), 507–517.
220. Ye, C., Choi, J.G., Abraham, S., Shankar, P., Manjunath, N., Targeting DNA vaccines to myeloid cells using a small peptide. European Journal of Immunology 45 (2014), 82–88.
221. Yu, Z., Tan, Z., Lee, B.K., Tang, J., Wu, X., Cheung, K.-W.,.. Chen, Z., Antigen spreading-induced CD8 + T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. Oncotarget 6 (2015), 32426–32438.
222. Zhang, H., Tang, K., Zhang, Y., Ma, R., Ma, J., Li, Y., Luo, S., Liang, X., Ji, T., Gu, Z., et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling. Cancer Immunology Research 3 (2014), 196–205.
223. Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D.,.. Amigorena, S., Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nature Medicine 4 (1998), 594–600.